Three different premixed combinations of biphasic insulin aspart - Comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue 7, 2009, Pages 700-708

  Cucinotta, D ^a   Smirnova, O ^b   Christiansen, J S ^c   Kanc, K ^d   le Devehat, C ^e   Wojciechowska, M ^f   Lopez de la Torre M ^g   Liebl, A ^h  

^a UNIVERSITY OF MESSINA   (Italy)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NOVO NORDISK A S   (Denmark)

^e Hôpital Pierre Bérégovoy   (France)

^f Grupowa Praktyka Lekarska   (Poland)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h Diabeteszentrum   (Germany)

Author keywords

Biphasic insulin aspart 30; Biphasic insulin aspart 50; Biphasic insulin aspart 70; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; METFORMIN;

ADULT; AGE; ARTICLE; BODY MASS; BRUGADA SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ETHNICITY; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; SEX RATIO; SIDE EFFECT; WEIGHT;

EID: 70449493183     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01035.x     Document Type: Article

References (11)

1. Standards of medical care in diabetes. Diabetes Care 2005, 28:S4-S36.
2. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006, 23:579-593.
3. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002, 19:393-399.
4. Schwartz S, Zagar A, Althouse S, Pinaire J, Holcombe J. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther 2006, 28:1649-1657.
5. Ligthelm R, Mouritzen U, Lyngaard H. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114:511-519.
6. Hamili S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005, 27(Suppl. B):S57-S74.
7. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003, 5:446-454.
8. Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycemic control in patients with type 2 diabetes. Diabetes Obes Metab 2003, 5:438-445.
9. Ligthelm RJ, Mouritzen U, Lynggaard H. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes 2006, 114:511-519.
10. Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ. Improved glycemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2007, 1:1-9.
11. Overview of 6 years therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44:1249-1258.